TY - JOUR T1 - <em>APOE</em>ε4 carriership associates with microglial activation independently of Aβ plaques and tau tangles JF - medRxiv DO - 10.1101/2022.07.12.22277556 SP - 2022.07.12.22277556 AU - João Pedro Ferrari-Souza AU - Firoza Z. Lussier AU - Douglas T. Leffa AU - Joseph Therriault AU - Cécile Tissot AU - Bruna Bellaver AU - Pâmela C. Lukasewicz Ferreira AU - Maura Malpetti AU - Yi-Ting Wang AU - Guilherme Povala AU - Andréa L. Benedet AU - Nicholas J. Ashton AU - Mira Chamoun AU - Stijn Servaes AU - Gleb Bezgin AU - Min Su Kang AU - Jenna Stevenson AU - Nesrine Rahmouni AU - Vanessa Pallen AU - Nina Margherita Poltronetti AU - John T. O’Brien AU - James B. Rowe AU - Ann D. Cohen AU - Oscar L. Lopez AU - Dana L. Tudorascu AU - Thomas K. Karikari AU - William E. Klunk AU - Victor L. Villemagne AU - Jean-Paul Soucy AU - Serge Gauthier AU - Diogo O. Souza AU - Henrik Zetterberg AU - Kaj Blennow AU - Eduardo R. Zimmer AU - Pedro Rosa-Neto AU - Tharick A. Pascoal Y1 - 2022/01/01 UR - http://medrxiv.org/content/early/2022/07/13/2022.07.12.22277556.abstract N2 - Microglial activation is an early phenomenon in Alzheimer’s disease (AD) that may occur prior to and independently of amyloid-β (Aβ) aggregation. Recent studies in transgenic animal models suggest that the apolipoprotein E ε4 (APOEε4) allele may be a culprit of early microglial activation in AD. However, it is unclear whether the APOEε4 genotype is associated with microglial reactivity in the living human brain. Here, we tested whether APOEε4 carriership is associated with microglial activation in individuals across the aging and AD spectrum. We studied 118 individuals who had positron emission tomography (PET) for Aβ ([18F]AZD4694), tau ([18F]MK6240), and microglial activation ([11C]PBR28), as well as clinical, genetic, and magnetic resonance imaging data. We found that APOEε4 carriership was associated with increased microglial activation mainly in early Braak-staging regions within the medial temporal cortex, and this effect of APOEε4 was independent of Aβ and tau deposition. Furthermore, microglial activation mediated the Aβ-independent effects of APOEε4 on downstream tau accumulation, neurodegeneration, and clinical impairment. Interestingly, the physiological distribution of APOE mRNA expression, obtained from the Allen Human Atlas, predicted the patterns of APOEε4-related microglial activation in our population, suggesting that the deleterious effects of APOEε4 occur at the level of gene expression. These results support a model in which the APOEε4 has Aβ-independent effects on AD pathogenesis by activating microglia in brain regions associated with early tau deposition. Our findings provide a rationale for the development of novel AD therapies targeting the interplay between ApoE and neuroinflammation.Competing Interest StatementSG has served as a scientific advisor to Cerveau Therapeutics. HZ has served at scientific advisory boards and/or as a consultant for Abbvie, Alector, Annexon, Apellis, Artery Therapeutics, AZTherapies, CogRx, Denali, Eisai, Nervgen, Novo Nordisk, Pinteon Therapeutics, Red Abbey Labs, reMYND, Passage Bio, Roche, Samumed, Siemens Healthineers, Triplet Therapeutics, and Wave, has given lectures in symposia sponsored by Cellectricon, Fujirebio, Alzecure, Biogen, and Roche, and is a co-founder of Brain Biomarker Solutions in Gothenburg AB (BBS), which is a part of the GU Ventures Incubator Program. KB has served as a consultant, at advisory boards, or at data monitoring committees for Abcam, Axon, BioArctic, Biogen, JOMDD/Shimadzu. Julius Clinical, Lilly, MagQu, Novartis, Prothena, Roche Diagnostics, and Siemens Healthineers, and is a co-founder of Brain Biomarker Solutions in Gothenburg AB (BBS), which is a part of the GU Ventures Incubator Program. ERZ serves in the scientific advisory board of Next Innovative Therapeutics. All other authors declare that they have no competing interests.Funding StatementThe Funding Statement is reported in the manuscript.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study was approved by the Douglas Mental Health University Institute Research Ethics Board and the Montreal Neurological Institute PET working committee, and all participants provided written informed consent.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data used in the present work is not publicly available as the information could compromise the participants′ privacy. Therefore, the data from the TRIAD study will be made available from the senior authors upon reasonable request, and such arrangements are subject to standard data-sharing agreements. ER -